Julie Lepin

Julie Lepin holds a substantial leadership role in regulatory affairs spanning over two decades, currently serving as Senior Vice President and Chief Regulatory Officer at BeiGene since September 2024. Previous positions include Senior Vice President at Mural Oncology and Sana Biotechnology, where Julie devised regulatory strategies across diverse therapeutic areas, including oncology and CNS. Other notable roles include Vice President of Regulatory Affairs at Amgen, leading the global regulatory strategy for a significant oncology portfolio, and pivotal leadership positions at Merck, Juno Therapeutics, and Galderma. Julie began their career at Baxter Healthcare and possesses a Master of Arts in Regulatory Affairs from Cardiff University, a Bachelor of Science in Biochemistry and Molecular Biology, and a Diploma in Theology and Ethics from King's College London.